Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Multi-center, Phase 1b/2a Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Association With Teplizumab in Patients With Clinical Recent-onset Type 1 Diabetes Mellitus (T1D)

NCT03751007 is registered in ClinicalTrials.gov with Precigen Actobio T1D, LLC as lead sponsor.

NCT NCT03751007
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03751007 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Multi-center, Phase 1b/2a Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Association With Teplizumab in Patients With Clinical Recent-onset Type 1 Diabetes Mellitus (T1D)
Lead sponsor
Precigen Actobio T1D, LLC
Phase
Phase 1/2
Overall status
Completed
Start date
October 24, 2018
Completion date
October 13, 2021
Enrollment
45 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes type1